الفهرس 
Refractory Status EpilepticusOnly 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
Inflammatory mechanisms have been increasingly implicated in the origin of seizures and epilepsy. Previous studies show an increase in some pro inflammatory cytokines in serum
after seizures, especially in cases of refractory repetitive acute seizures such as new-onset refractory status epilepticus (NORSE) or febrile infection-related epilepsy syndrome.Interleukin-6 (IL-6) is elevated in refractory repetitive seizures and it plays a major role
in inflammation-mediated neuronal damage.Tocilizumab is an interleukin (IL)-6 receptor inhibitor that blocks IL-6–mediated signal transduction. This drug is known to improve various autoimmune diseases because IL-6 plays
an important role in autoimmune processes. Although recent studies have identified a clinical benefit of tocilizumab in refractory central nervous system autoimmune disorders, such as autoimmune encephalitis and neuromyelitis optica, its efficacy has not been investigated in patients with refractory status epilepticus.